ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0036496;regulation of translational initiation by eIF2 alpha dephosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.608321545174602;674.6262540571083;9.083926447120524;0.022579133599080606;0.8797934328124444;[PPP1CA]
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[PRL, HGS]
GO:0036498;IRE1-mediated unfolded protein response;6.0;1.0;0.8231203125901445;9.628524252492122;55.46397693329154;5.825829909099042;0.0018563293936187412;0.6210535250702663;[TLN1]
GO:1990090;cellular response to nerve growth factor stimulus;6.0;0.9326813400603323;0.7894609826203107;9.5544162803384;97.48528473772916;5.9928839937622085;0.003262744749111514;0.6295966787287501;[AKT1]
GO:1901224;positive regulation of NIK/NF-kappaB signaling;8.0;0.9326813400603323;0.8413406700301662;9.571365838652174;238.82315740091596;5.572381008289503;0.007993196151321231;0.6599718239061428;[ACTN4]
GO:0071380;cellular response to prostaglandin E stimulus;8.0;1.0;0.875;9.628524252492122;704.3614414198233;6.943860283624253;0.023574343560179453;0.7301093378270707;[AKT1]
GO:0002244;hematopoietic progenitor cell differentiation;4.0;0.811012628672052;0.655506314336026;8.935377071932177;21.066225782797595;5.395046993006588;7.050676185779127E-4;0.5259029541176994;[TGFB1]
GO:0071372;cellular response to follicle-stimulating hormone stimulus;7.0;1.0;0.8509193652572005;9.628524252492122;138.479565017491;7.379178354882098;0.004634786417618152;0.728290889492758;[POR]
GO:0000188;inactivation of MAPK activity;13.0;0.8436909121759173;0.8844004208555951;9.558319993818873;2610.871803759405;6.518977089658987;0.08738352963975493;0.7959357562962344;[PPP2R1A]
GO:0000184;nuclear-transcribed mRNA catabolic process, nonsense-mediated decay;10.0;0.8933024483968273;0.861892236059334;9.57851383191746;717.2549128915896;4.989581884898423;0.0240058764469685;0.6704084614939124;[PPP2R1A]
GO:0000060;protein import into nucleus, translocation;9.0;1.0;0.896240625180289;9.628524252492122;93.4429707305496;6.444869117505266;0.0031274521371376313;0.7258315315665724;[TGFB1, POLA2, AKT1, RAN]
GO:0071375;cellular response to peptide hormone stimulus;7.0;0.7369933605727446;0.7194160455435727;9.117698628726131;386.0268190343683;4.727217620430932;0.012919970231498398;0.5926694942041391;[AKT1, LHCGR, POR, TGFB1, CDC6]
GO:0030948;negative regulation of vascular endothelial growth factor receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;297.5747140953686;7.474488534686424;0.00995955788091634;0.7331650565203278;[HGS]
GO:0050435;amyloid-beta metabolic process;6.0;0.9326813400603323;0.7894609826203107;9.533214072687796;60.01596331221528;6.943860283624253;0.0020086802811995464;0.6782296504172152;[APEH]
GO:0050679;positive regulation of epithelial cell proliferation;6.0;0.7192862368539868;0.682763431017138;8.647694999480395;65.06748660449396;4.584116776790259;0.002177750219716307;0.5575522577384293;[CDH3, AKT1, MMP12, TGFB1]
GO:2000010;positive regulation of protein localization to cell surface;7.0;1.0;0.8509193652572005;9.628524252492122;73.70707873031733;7.004484905440688;0.002466909593039506;0.7091290490632969;[AKT1]
GO:1900025;negative regulation of substrate adhesion-dependent cell spreading;8.0;1.0;0.875;9.628524252492122;367.370684139938;7.212124270218933;0.012295566186013157;0.7438283705770736;[ACTN4]
GO:0048009;insulin-like growth factor receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;31.002284443533863;7.138016298065211;0.0010376185600805164;0.7400384854347593;[AKT1, TSC2]
GO:1903533;regulation of protein targeting;8.0;0.7090535922965819;0.729526796148291;9.148951172230236;93.33385198544636;5.370354380416217;0.003123800030939521;0.649640172761504;[, NUCB1]
GO:1900026;positive regulation of substrate adhesion-dependent cell spreading;8.0;1.0;0.875;9.628524252492122;350.51777089970517;6.280566066213989;0.011731514346499779;0.6961884407023742;[DNM2, FLNA]
GO:0006611;protein export from nucleus;9.0;0.7508913569872202;0.7716863036738992;9.277126365654233;128.4390295807893;5.948432231191374;0.00429873873244698;0.7004437261138039;[, XPO1, NUP62, NUP88, TGFB1, NUPL2, RAN]
GO:0006974;cellular response to DNA damage stimulus;4.0;0.5696777571895439;0.534838878594772;7.469040003138749;28.997869804256865;3.161008442547652;9.705326059599744E-4;0.4116541187538124;[AKT1, SFN, UNG, GTF2H1, CNOT3, RFC1, SMC1A, E2F7, RAD51, CCNH, PCNA, DCLRE1A, HMGA1, POLE2]
GO:1900029;positive regulation of ruffle assembly;9.0;1.0;0.896240625180289;9.628524252492122;200.30665838708023;7.138016298065211;0.006704083591926775;0.7612791106150483;[EPS8L1, PFN1]
GO:1903538;regulation of meiotic cell cycle process involved in oocyte maturation;9.0;0.8933024483968273;0.8428918493787028;9.517298617381897;148.22274980760076;9.083926447120524;0.0049608820442461005;0.8607930461318132;[PPP2R1A]
GO:0050680;negative regulation of epithelial cell proliferation;6.0;0.7307253602413294;0.6884829927108091;8.690254613899192;65.19530579150691;4.989581884898423;0.0021820282128758306;0.5782877622231366;[PRL, SFN, TGFB1]
GO:0071364;cellular response to epidermal growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;6.088194173566533;0.003262744749111514;0.63447084575632;[AKT1]
GO:2000249;regulation of actin cytoskeleton reorganization;8.0;0.8933024483968273;0.8216512241984136;9.427853557029971;36.19570401534177;6.221725566191056;0.0012114376393747596;0.6931793347948383;[TGFB1]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[FGF5, TGFB1]
GO:0051898;negative regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.79440420981607;6.063501560976162;0.00799223380789131;0.6850877518099798;[TSC2, AKT1]
GO:1903543;positive regulation of exosomal secretion;9.0;1.0;0.896240625180289;9.628524252492122;273.97956964224545;7.069023426578259;0.009169849630321672;0.757750811958709;[HGS]
GO:0060389;pathway-restricted SMAD protein phosphorylation;8.0;1.0;0.875;9.628524252492122;180.75330000196035;7.212124270218933;0.006049650283656873;0.7438283705770736;[TGFB1]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ACTN4, TLN1, STXBP2, FLNA, TGFB1]
GO:0000165;MAPK cascade;9.0;0.7436939687323844;0.7680876095464813;9.236482164716097;231.45054935470895;4.069963362931594;0.007746441594931149;0.6043787408332628;[FGF5, MAP2K2, TGFB1, SPTAN1, MAP4K1]
GO:0048384;retinoic acid receptor signaling pathway;6.0;0.7866048967936545;0.7164227609869718;8.935377071932177;25.568165535828406;7.004484905440688;8.557434906291208E-4;0.6813299963962409;[NR1H2, ACTN4]
GO:0051781;positive regulation of cell division;5.0;0.6763753087927167;0.6284286662572787;8.438940185618286;42.28939918509474;5.358233019883872;0.0014153881327367882;0.5642612976810992;[FGF5, NUP62, TGFB1, CDC6, CIT]
GO:0048146;positive regulation of fibroblast proliferation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;63.74573076450893;5.825829909099042;0.0021335122412550348;0.6210535250702663;[TGFB1, CDC6]
GO:0006816;calcium ion transport;8.0;0.6696747006330769;0.7098373503165385;8.690254613899192;35.67391733828006;4.3132418226548594;0.001193973908871026;0.5955793873968269;[CORO1A, ATP2A3]
GO:0071276;cellular response to cadmium ion;6.0;1.0;0.8231203125901445;9.628524252492122;78.50383844342444;6.139487467954083;0.0026274528238337297;0.6370939872166814;[AKT1]
GO:0071158;positive regulation of cell cycle arrest;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;83.12201169572153;5.395046993006588;0.002782018926502022;0.6268223193749;[PCNA, SFN, E2F7, TGFB1, CNOT3]
GO:0060391;positive regulation of SMAD protein signal transduction;8.0;1.0;0.875;9.628524252492122;234.98809543662418;7.292166977892469;0.007864840078708074;0.747921758369865;[TGFB1]
GO:0051306;mitotic sister chromatid separation;4.0;1.0;0.75;9.628524252492122;27.51648075733887;8.67846133901236;9.20951847723215E-4;0.6938169164668168;[PPP2R1A]
GO:2001224;positive regulation of neuron migration;8.0;0.8933024483968273;0.8216512241984136;9.59462270081644;536.247192550588;7.138016298065211;0.017947710943527356;0.7400384854347593;[FLNA]
GO:2001240;negative regulation of extrinsic apoptotic signaling pathway in absence of ligand;10.0;1.0;0.9152410118609203;9.628524252492122;570.2036429558796;6.221725566191056;0.019084202779771145;0.7334203466557586;[AKT1]
GO:2001241;positive regulation of extrinsic apoptotic signaling pathway in absence of ligand;10.0;1.0;0.9152410118609203;9.628524252492122;424.359905324836;7.292166977892469;0.01420294413210246;0.7881627702307852;[PPP2R1A, PPP1CA]
GO:1903799;negative regulation of production of miRNAs involved in gene silencing by miRNA;10.0;0.8933024483968273;0.861892236059334;9.5758805190067;949.8698671053862;7.697632086000634;0.031791289624636974;0.8088982747154926;[TGFB1]
GO:0005981;regulation of glycogen catabolic process;9.0;0.8933024483968273;0.8428918493787028;9.52844079393514;259.5639280205376;7.9853141584524145;0.008687371078478277;0.8046099625986299;[PPP1CA]
GO:1904886;beta-catenin destruction complex disassembly;5.0;1.0;0.7902410118609202;9.628524252492122;38.04764185170599;6.7325511899570465;0.0012734203321220245;0.6345439928109722;[PPP1CA]
GO:0071260;cellular response to mechanical stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;56.1235610070294;5.420364800990877;0.00187840507897962;0.5674387198563348;[AKT1, TGFB1]
GO:0005978;glycogen biosynthetic process;8.0;1.0;0.875;9.628524252492122;798.0491347435755;6.781341354126479;0.026709986342275536;0.7217981122146513;[AKT1]
GO:0005977;glycogen metabolic process;7.0;0.8653626801206646;0.7836007053175329;9.523163736834295;182.57737249811964;5.885253329569843;0.006110700348544658;0.6518914942236709;[AKT1, PPP1CA]
GO:0005979;regulation of glycogen biosynthetic process;9.0;0.8933024483968273;0.8428918493787028;9.541512875502493;342.46968566496105;6.481236761676141;0.011462152176499362;0.7276913745807394;[AKT1, PPP1CA]
GO:2001234;negative regulation of apoptotic signaling pathway;8.0;0.6913464685778243;0.7206732342889122;9.146686165599384;292.02860154420875;4.420487353008457;0.00977393448500626;0.601063928806537;[AKT1, GNAI2]
GO:0021915;neural tube development;5.0;1.0;0.7902410118609202;9.628524252492122;33.009488292418915;6.409777797693995;0.0011047978665365144;0.618037346520142;[TGFB1, NUP133]
GO:1901666;positive regulation of NAD+ ADP-ribosyltransferase activity;6.0;1.0;0.8231203125901445;9.628524252492122;49.122279745261444;8.67846133901236;0.0016440784958923031;0.7669372290569613;[TGFB1]
GO:1903721;positive regulation of I-kappaB phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;1064.5221611191064;8.67846133901236;0.035628598724910615;0.8590579283277371;[AKT1]
GO:0030866;cortical actin cytoskeleton organization;6.0;0.7671156992804218;0.7066781622303554;9.117698628726131;53.946853691669205;6.088194173566533;0.0018055526440439148;0.63447084575632;[TLN1]
GO:0032801;receptor catabolic process;6.0;0.8436909121759173;0.7449657686781032;9.34084218004034;102.12013474586499;6.518977089658987;0.003417869007789623;0.6565011041187423;[TGFB1, AP2M1]
GO:0032922;circadian regulation of gene expression;6.0;1.0;0.8231203125901445;9.628524252492122;31.18462308171688;5.769740442447999;0.0010437212702063816;0.618185107137305;[PPP1CA]
GO:0006878;cellular copper ion homeostasis;10.0;0.8653626801206646;0.8479223519212526;9.523163736834295;186.04478652569694;7.138016298065211;0.006226751575577643;0.7802794972956796;[CCDC22]
GO:0030509;BMP signaling pathway;11.0;0.7090535922965819;0.7869557484779532;9.133828010656014;282.55034729266697;5.202362649177086;0.009456705845082177;0.6984780201431826;[TGFB1]
GO:0071456;cellular response to hypoxia;6.0;1.0;0.8231203125901445;9.628524252492122;103.24589989147204;5.104244793218563;0.0034555473540902374;0.5841516286869992;[AKT1]
GO:0030501;positive regulation of bone mineralization;7.0;0.9326813400603323;0.8172600352873667;9.55953138100517;171.85898464291293;6.221725566191056;0.005751965552953692;0.6690987000520388;[TGFB1]
GO:1901796;regulation of signal transduction by p53 class mediator;7.0;0.7192862368539868;0.710562483684194;9.117698628726131;45.070113835906206;4.948759890378168;0.001508456149618737;0.6039991761920099;[AKT1]
GO:0006893;Golgi to plasma membrane transport;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;32.11060110714162;5.845247994956144;0.0010747129213912287;0.6498456195510879;[DNM2, CCDC22]
GO:0060312;regulation of blood vessel remodeling;5.0;0.8259837884571596;0.7032329060895001;9.377209824211215;28.902788426864877;7.57984905034425;9.673503178263487E-4;0.6778748447945537;[TGFB1]
GO:1903614;negative regulation of protein tyrosine phosphatase activity;11.0;1.0;0.9324289523296623;9.628524252492122;1252.1557676251311;9.777073627680469;0.04190852667538468;0.9324289523296623;[GNAI2]
GO:0006412;translation;7.0;0.8653626801206646;0.7836007053175329;9.510741216835738;402.5585345733233;4.39257856489138;0.01347327187300917;0.5755560373415389;[AKT1]
GO:0071560;cellular response to transforming growth factor beta stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;97.48528473772916;5.788089581116195;0.003262744749111514;0.6191234829421188;[TGFB1]
GO:0006888;ER to Golgi vesicle-mediated transport;6.0;1.0;0.8231203125901445;9.628524252492122;49.13394272044514;4.493869898942481;0.001644468845175705;0.5529370282083849;[, NRBP1, SPTAN1]
GO:0045066;regulatory T cell differentiation;7.0;0.8653626801206646;0.7836007053175329;9.485423408851448;66.99450330244977;8.390779266560578;0.002242245734394454;0.7800242071602487;[TGFB1]
GO:0072657;protein localization to membrane;5.0;0.5756379274792419;0.5780599756005412;7.585450354983161;29.829169826127035;3.7017275965917853;9.983554695705216E-4;0.4795475332985618;[JUP, FLNA, CDH1, HGS, NUP155, NUP54]
GO:0072656;maintenance of protein location in mitochondrion;7.0;1.0;0.8509193652572005;9.628524252492122;48.00389740763819;8.16763571524637;0.0016066472455308106;0.7686126355688037;[AKT1]
GO:0072655;establishment of protein localization to mitochondrion;7.0;0.7671156992804218;0.7344772148974115;9.117698628726131;87.58932464406844;5.587418885654044;0.002931535870562561;0.6366602269110988;[AKT1]
GO:0072659;protein localization to plasma membrane;6.0;0.7866048967936545;0.7164227609869718;9.260799472366804;65.42666064804821;4.677207199856271;0.002189771451718415;0.5623129063031725;[CDH1, FLNA, JUP]
GO:0050765;negative regulation of phagocytosis;8.0;0.8436909121759173;0.7968454560879586;9.503361109538115;175.4194889364855;7.069023426578259;0.005871132427413739;0.7365101867784198;[TGFB1]
GO:0016567;protein ubiquitination;9.0;0.6913464685778243;0.7419138594692012;8.996001693748612;153.79381005389072;3.300101264790787;0.005147340417060716;0.5650079573320931;[AKT1, SKP2, PCNA, UBE2M, HIST1H2BK]
GO:0035066;positive regulation of histone acetylation;11.0;0.811012628672052;0.8379352666656883;9.498471124243924;1302.9179711131005;6.444869117505266;0.043607491943109866;0.7620198587159455;[TGFB1]
GO:0014003;oligodendrocyte development;5.0;1.0;0.7902410118609202;9.628524252492122;34.09911675737102;6.558197802812269;0.001141266750656509;0.6256275524841266;[TGFB1]
GO:2000060;positive regulation of ubiquitin-dependent protein catabolic process;10.0;0.811012628672052;0.8207473261969463;9.483342242647623;1661.590298646008;5.192106149009898;0.055611931961498426;0.6807655617789147;[AKT1, CCDC22]
GO:1902895;positive regulation of pri-miRNA transcription by RNA polymerase II;12.0;1.0;0.9481203125901445;9.628524252492122;1721.2385553242598;6.599019797332524;0.0576083054325737;0.7855944919115336;[TGFB1, PRL]
GO:1901203;positive regulation of extracellular matrix assembly;7.0;1.0;0.8509193652572005;9.628524252492122;123.61133381433942;8.16763571524637;0.004137160099788013;0.7686126355688037;[TGFB1]
GO:1903506;regulation of nucleic acid-templated transcription;8.0;0.4030666779312405;0.5765333389656202;6.659820651326051;149.90042129525023;1.545963787352316;0.005017032199131414;0.4540606599798657;[NUP107, AKT1, JUP, MMP12, ATAD2, PKN1, GMNN, E2F7, FBXO5, ACTN4, PCNA, NR3C2, NUP133, NUP85, ZNF367, EPCAM, NR1H2, TLE4, MAP2K2, CCDC22, RFC1, PPP2R1A, IFNA2, PRL, XPO1, MLF2, CBX4, DNM2, EHMT2, EZH2, FLNA, MAZ, CCNH, HMGA1, NUP62, NUP35, RAN, EHF, HOXA9, CDC6, BRD2, AES, GTF2H1, CDH1, CNOT3, PFN1, RHOG, ARID4A, TGFB1, MEIS2]
GO:0006622;protein targeting to lysosome;11.0;0.9326813400603323;0.8987696223598284;9.592156608321247;250.3799473132135;6.781341354126479;0.008379991509250163;0.7792270645443136;[HGS]
GO:0070262;peptidyl-serine dephosphorylation;8.0;1.0;0.875;9.628524252492122;179.24922260518233;7.292166977892469;0.005999310166768488;0.747921758369865;[PPP2R1A, PPP1CA]
GO:1904707;positive regulation of vascular smooth muscle cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;80.75549718811011;6.444869117505266;0.0027028138156570515;0.6805102716434839;[GNAI2]
GO:0000086;G2/M transition of mitotic cell cycle;5.0;1.0;0.7902410118609202;9.628524252492122;43.44612409677276;4.981283082083729;0.0014541026745458175;0.5449840603320351;[PPP2R1A, SKP2, CIT, DNM2, MELK, PKMYT1, WEE1]
GO:0071353;cellular response to interleukin-4;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;6.599019797332524;0.0027327542132076126;0.6605944919115335;[CORO1A, MCM2]
GO:0071479;cellular response to ionizing radiation;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;48.660440229648614;5.602686357784832;0.0016286211429333208;0.6096419534788213;[TGFB1, DNM2, RAD51]
GO:2000179;positive regulation of neural precursor cell proliferation;6.0;0.8259837884571596;0.7361122068187242;9.186691500213083;64.30534655244489;6.015873511986907;0.00215224207805574;0.6307723637598831;[GNAI2, FLNA]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[AKT1]
GO:1900126;negative regulation of hyaluronan biosynthetic process;9.0;1.0;0.896240625180289;9.628524252492122;591.2837729800367;8.67846133901236;0.019789735760794357;0.8400575416471059;[TGFB1]
GO:0031929;TOR signaling;6.0;0.8653626801206646;0.7558016526504768;9.377209824211215;26.42836680105094;6.518977089658987;8.845336528452411E-4;0.6565011041187423;[AKT1]
GO:1901215;negative regulation of neuron death;6.0;0.7586651285174919;0.7024528768488905;9.05316010758856;58.54459561550999;4.545965010825883;0.001959434928535777;0.5556011746527726;[AKT1, CORO1A]
GO:0006754;ATP biosynthetic process;11.0;0.7043150770688792;0.7845864908641018;9.424925297250882;8670.873920960137;5.433268205826786;0.29020634685463875;0.7102865410484548;[TGFB1]
GO:0060336;negative regulation of interferon-gamma-mediated signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;644.7745418141438;7.8311634786251565;0.021580023655105394;0.7967266896635242;[NR1H2]
GO:0006874;cellular calcium ion homeostasis;9.0;0.6324783794010864;0.7124798148808322;8.83001655627435;287.08247441589424;3.7781370657337865;0.009608392061246992;0.5894547304232562;[TGFB1, ATP2A3]
GO:0071222;cellular response to lipopolysaccharide;6.0;1.0;0.8231203125901445;9.628524252492122;237.99812851129587;4.786641040901733;0.007965583176863442;0.5679093580234316;[NR1H2]
GO:0030837;negative regulation of actin filament polymerization;11.0;0.8436909121759173;0.8542744084176208;9.536150932361107;433.7598075732239;5.8067817141283475;0.014517550400993206;0.7293880392331511;[SPTAN1, PFN1]
GO:0045087;innate immune response;4.0;0.6799073451904818;0.5899536725952409;8.162187183698695;26.470038109745843;3.422703586883119;8.859283540455166E-4;0.42503722060519694;[, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, IFNA14, IFNA16, IFNA10, CORO1A, IFNA21, TGFB1, HIST1H2BK]
GO:0097711;ciliary basal body-plasma membrane docking;5.0;1.0;0.7902410118609202;9.628524252492122;21.38880323109876;5.223196736079928;7.158639954716971E-4;0.5573555358475362;[PPP2R1A]
GO:0070374;positive regulation of ERK1 and ERK2 cascade;11.0;0.9326813400603323;0.8987696223598284;9.604993755081928;1178.864923326294;4.330336256014159;0.03945554807418015;0.6538825498434562;[TGFB1, GNAI2]
GO:0006508;proteolysis;5.0;0.5517781253862416;0.5661300745540411;7.338517941704937;47.85814540089318;2.5985281439167696;0.001601769057033345;0.42312986198474045;[, ST14, MMP12, APEH, ADAMTS20, SKP2, RANBP1, TGFB1]
GO:0030838;positive regulation of actin filament polymerization;11.0;0.7866048967936545;0.8257314007264895;9.456673995565463;459.92540939869633;5.2552850506314295;0.01539328954657896;0.7011844742147011;[PFN1]
GO:0071346;cellular response to interferon-gamma;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;5.266214121163619;0.0027327542132076126;0.5924347476504533;[STXBP2, ZYX]
GO:0036258;multivesicular body assembly;7.0;1.0;0.8509193652572005;9.628524252492122;62.72328125453724;6.375876246018314;0.0020992917763011008;0.6769819729871445;[HGS]
GO:0051754;meiotic sister chromatid cohesion, centromeric;7.0;1.0;0.8509193652572005;9.628524252492122;116.99733732322595;8.16763571524637;0.003915795589440837;0.7686126355688037;[PPP2R1A]
GO:0019932;second-messenger-mediated signaling;6.0;0.6547035408479693;0.6504720830141292;8.316337863525954;26.42836680105094;4.103750360508977;8.845336528452411E-4;0.5329862968704817;[PPP2R1A, LHCGR, GNAI2]
GO:0014065;phosphatidylinositol 3-kinase signaling;8.0;1.0;0.875;9.628524252492122;26.42836680105094;6.343086423195323;8.845336528452411E-4;0.6993857346658935;[AKT1]
GO:0015031;protein transport;7.0;0.4793097133439409;0.590574221929171;6.989466922876863;54.45792783373929;2.578890050578526;0.0018226578356421344;0.4828039223744382;[, NUP107, AKT1, MMP12, AP2M1, ACAP1, ITGB6, ACTN4, POLA2, NUP155, NASP, NUP62, NUP133, NUP54, NUP35, RAN, NUP85, NUP88, CCDC22, STXBP2, XPO1, RANBP1, NUPL2, TSC2, HGS, TGFB1, DNM2]
GO:0085029;extracellular matrix assembly;5.0;0.7980440201809971;0.6892630219514189;9.176539128749065;38.15502461274271;6.7325511899570465;0.0012770143364957127;0.6345439928109722;[TGFB1]
GO:0042532;negative regulation of tyrosine phosphorylation of STAT protein;11.0;1.0;0.9324289523296623;9.628524252492122;1231.6194323740242;7.379178354882098;0.041221194016031935;0.8098004765652196;[PPP2R1A]
GO:0051126;negative regulation of actin nucleation;12.0;0.9326813400603323;0.9144609826203107;9.59573442966913;318.2257087533811;7.697632086000634;0.010650728087431447;0.8417775754447168;[CORO1A]
GO:0030307;positive regulation of cell growth;6.0;0.6954798709641801;0.6708602480722345;8.712233520617966;80.64681300048527;4.733648510761223;0.0026991762537066665;0.5651993175676412;[AKT1, SFN]
GO:0007406;negative regulation of neuroblast proliferation;8.0;0.8933024483968273;0.8216512241984136;9.5544162803384;502.0817198454759;8.390779266560578;0.016804223319016428;0.8041048419030481;[TGFB1]
GO:0032967;positive regulation of collagen biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;105.22247330055487;6.558197802812269;0.003521701487291661;0.6585068532133508;[TGFB1]
GO:0031999;negative regulation of fatty acid beta-oxidation;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;724.8195482541148;8.16763571524637;0.024259057984822387;0.8139338954918922;[AKT1]
GO:0051000;positive regulation of nitric-oxide synthase activity;7.0;1.0;0.8509193652572005;9.628524252492122;123.23454311126406;6.832634648514029;0.0041245492540456985;0.7003406189322132;[AKT1]
GO:0097368;establishment of Sertoli cell barrier;6.0;1.0;0.8231203125901445;9.628524252492122;53.96940310801916;8.16763571524637;0.0018063073527159906;0.7408135829017477;[ARID4A, FLNA]
GO:0030308;negative regulation of cell growth;6.0;0.6913464685778243;0.6687935468790567;8.673012807464685;80.89021177018715;4.623782033182691;0.0027073225914839173;0.5595807407949613;[PPP2R1A, TNR, TGFB1, SIPA1]
GO:0010936;negative regulation of macrophage cytokine production;8.0;1.0;0.875;9.628524252492122;311.05347994333346;8.16763571524637;0.010410680043746014;0.7926932703116032;[TGFB1]
GO:2001046;positive regulation of integrin-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;186.95064880168647;7.9853141584524145;0.006257069970731893;0.7592887026755414;[FLNA]
GO:0051006;positive regulation of lipoprotein lipase activity;8.0;1.0;0.875;9.628524252492122;65.27546671602516;7.57984905034425;0.002184711126879308;0.7626338329336335;[NR1H2]
GO:0140199;negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathway involved in heart process;11.0;1.0;0.9324289523296623;9.628524252492122;664.6059319467631;9.083926447120524;0.02224376243575177;0.8969813732811862;[GNAI2]
GO:0042789;mRNA transcription by RNA polymerase II;11.0;1.0;0.9324289523296623;9.628524252492122;1288.3918881325048;6.832634648514029;0.043121317018375266;0.781850206004675;[FLNA]
GO:0042307;positive regulation of protein import into nucleus;9.0;0.9326813400603323;0.8625812952104552;9.592156608321247;778.7460608588023;6.063501560976162;0.02606392983099081;0.706328376990269;[CDH1, TGFB1, JUP]
GO:1905313;transforming growth factor beta receptor signaling pathway involved in heart development;9.0;0.9326813400603323;0.8625812952104552;9.541512875502493;60.43149861880159;9.777073627680469;0.0020225878739534935;0.896240625180289;[TGFB1]
GO:0021943;formation of radial glial scaffolds;6.0;1.0;0.8231203125901445;9.628524252492122;47.452274261266446;8.390779266560578;0.0015881849152503491;0.7522251544931926;[FLNA]
GO:0006334;nucleosome assembly;7.0;0.8653626801206646;0.7836007053175329;9.474373572664863;104.51542930890014;4.99795013456894;0.0034980373611892576;0.6065147675675062;[BRD2, MCM2, HIST1H2BK, H1FX, NASP]
GO:0097011;cellular response to granulocyte macrophage colony-stimulating factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;7.57984905034425;0.0027327542132076126;0.710754145523778;[AKT1]
GO:0051497;negative regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;338.83785420150645;6.781341354126479;0.01134059804585365;0.7792270645443136;[STMN1, PFN1, ARHGAP6]
GO:0016242;negative regulation of macroautophagy;8.0;0.7866048967936545;0.7683024483968273;9.283683766200392;266.4734130419696;6.343086423195323;0.0089186253240128;0.6993857346658935;[AKT1, TSC2]
GO:0051017;actin filament bundle assembly;6.0;0.7866048967936545;0.7164227609869718;9.143016436710422;39.792633402144126;5.734022359845919;0.001331823628924752;0.6163584827319739;[ACTN4, ZYX]
GO:0043406;positive regulation of MAP kinase activity;12.0;0.7043150770688792;0.8002778511245842;9.369013057007038;2605.6877929993507;4.201124524534153;0.08721002546492271;0.6629660161470909;[, MAP2K2, TGFB1, EZH2, MAP4K1, PKN1]
GO:0043405;regulation of MAP kinase activity;11.0;0.6634067003016617;0.7641323024804931;9.028903129943;322.70119747860093;3.951073520300019;0.0108005186673862;0.6344870359015141;[, PPP2R1A, EZH2, MAP4K1, PKN1, MAP2K2, HGS, TGFB1, NUP62]
GO:1902176;negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway;10.0;0.8653626801206646;0.8479223519212526;9.600353375525426;999.3623287810346;6.781341354126479;0.033447757776597226;0.7620391240755716;[AKT1]
GO:0002062;chondrocyte differentiation;4.0;0.8933024483968273;0.6966512241984136;9.446202695698167;21.066225782797595;6.039404009397101;7.050676185779127E-4;0.5588554019015759;[TGFB1]
GO:0051271;negative regulation of cellular component movement;5.0;0.5470854108181258;0.5637837172699831;7.364160372318274;52.38761662992485;4.128099389519264;0.001753366382809582;0.5013522066171892;[ACTN4, TGFB1, JUP]
GO:0022900;electron transport chain;4.0;0.7140352122741334;0.6070176061370667;8.475844742553736;29.758801740447502;4.623782033182691;9.96000313069993E-4;0.48646042820481683;[POR]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, AKT1, JUP, MMP12, EPCAM, NR1H2, ATAD2, GTF2H1, E2F7, CCNH, PRL, ARID4A, TGFB1, HMGA1, MEIS2]
GO:0043401;steroid hormone mediated signaling pathway;6.0;0.7508913569872202;0.6985659910837546;8.801845679307654;25.735219620490994;4.909539177224887;8.613346405038622E-4;0.5741943744303455;[NR3C2, NR1H2, RAN]
GO:0043525;positive regulation of neuron apoptotic process;8.0;0.8436909121759173;0.7968454560879586;9.392135474427892;179.36331192335928;5.885253329569843;0.0060031286335741505;0.6759721289664703;[UBE2M]
GO:0043524;negative regulation of neuron apoptotic process;8.0;0.7866048967936545;0.7683024483968273;9.245532000236016;179.62959498689688;4.864418741944418;0.006012040888071555;0.6237666006816429;[CORO1A]
GO:0006417;regulation of translation;7.0;0.5221699919663294;0.6120043612403652;8.01908634005802;212.8215771898108;3.9901762463137618;0.007122946661558481;0.554977164055858;[AKT1, PPP1CA, CNOT3]
GO:0006415;translational termination;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;39.9935520007603;5.223196736079928;0.001338548193605436;0.5902348365767605;[APEH]
GO:0010918;positive regulation of mitochondrial membrane potential;5.0;1.0;0.7902410118609202;9.628524252492122;24.658349685322438;7.57984905034425;8.252927728937918E-4;0.6778748447945537;[AKT1]
GO:0051146;striated muscle cell differentiation;5.0;0.7436939687323844;0.6620879962271125;8.781226392104918;21.75937296335754;5.825829909099042;7.282666309192915E-4;0.5881742243410422;[AKT1]
GO:0032700;negative regulation of interleukin-17 production;6.0;0.8653626801206646;0.7558016526504768;9.427853557029971;65.25422870398782;7.292166977892469;0.002184000309729388;0.6960420709600095;[TGFB1]
GO:0016236;macroautophagy;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;39.83166466328102;5.244474134527214;0.0013331299701091492;0.5584436629936305;[HGS]
GO:0016479;negative regulation of transcription by RNA polymerase I;11.0;0.8653626801206646;0.8651102923899945;9.548481544818586;1834.662418985909;8.16763571524637;0.06140450007447906;0.8501222226412654;[FLNA]
GO:0043537;negative regulation of blood vessel endothelial cell migration;10.0;0.9326813400603323;0.8815816818910864;9.584072489921288;356.3539069568923;6.311337724880743;0.01192684456815238;0.7380031166185408;[TGFB1, JUP]
GO:0051280;negative regulation of release of sequestered calcium ion into cytosol;10.0;0.8933024483968273;0.861892236059334;9.566003895510788;673.651588659943;7.212124270218933;0.02254651242537939;0.7840693824379941;[TGFB1]
GO:0006672;ceramide metabolic process;7.0;0.7140352122741334;0.7079369713942671;9.176539128749065;101.21355503378848;5.420364800990877;0.0033875266006951925;0.628117073252615;[PPP2R1A]
GO:0045955;negative regulation of calcium ion-dependent exocytosis;10.0;0.8259837884571596;0.8282329060895002;9.437469015729413;303.102574775246;7.379178354882098;0.010144570403120213;0.7926125360964777;[GNAI2]
GO:0043536;positive regulation of blood vessel endothelial cell migration;10.0;0.9326813400603323;0.8815816818910864;9.584072489921288;355.43002650478036;5.8067817141283475;0.011895923120858621;0.7122000987644093;[AKT1, TGFB1]
GO:0009817;defense response to fungus, incompatible interaction;7.0;1.0;0.8509193652572005;9.628524252492122;143.15190279508232;9.777073627680469;0.004791165358203135;0.8509193652572005;[TGFB1]
GO:0051279;regulation of release of sequestered calcium ion into cytosol;9.0;0.7369933605727446;0.7647373054666613;9.242861771680136;148.50473241193134;5.486614186532078;0.004970319748245178;0.676826329833192;[CORO1A, TGFB1]
GO:0051152;positive regulation of smooth muscle cell differentiation;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;145.28799013580416;7.292166977892469;0.004862658279143298;0.7238411236270654;[TGFB1]
GO:0010800;positive regulation of peptidyl-threonine phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;778.6672313762616;6.375876246018314;0.026061291479152104;0.7413036195908642;[TGFB1]
GO:0030512;negative regulation of transforming growth factor beta receptor signaling pathway;8.0;0.8933024483968273;0.8216512241984136;9.537552474286395;374.7458266990886;5.54296712308321;0.012542405570270547;0.6584675964488075;[TGFB1, DNM2]
GO:0032930;positive regulation of superoxide anion generation;8.0;1.0;0.875;9.628524252492122;144.57516735605006;7.004484905440688;0.00483880074220378;0.7332096838060964;[TGFB1, GNAI2]
GO:1901381;positive regulation of potassium ion transmembrane transport;9.0;0.7369933605727446;0.7647373054666613;9.271849308553389;341.4877247401287;6.311337724880743;0.01142928682805268;0.7190027299379095;[FLNA, DNM2]
GO:0032770;positive regulation of monooxygenase activity;6.0;0.8259837884571596;0.7361122068187242;9.303101852057495;96.20735530608412;6.518977089658987;0.0032199736010961747;0.6565011041187423;[POR, CDH3, AKT1]
GO:0007213;G-protein coupled acetylcholine receptor signaling pathway;7.0;0.7980440201809971;0.7499413753476991;9.260799472366804;50.14720301582843;6.8867018697843045;0.001678381755387122;0.7031056191423581;[GNAI2]
GO:0006006;glucose metabolic process;6.0;0.7090535922965819;0.6776471087384355;8.572471578242808;34.676020684410545;5.040875179285974;0.0011605752059146955;0.5809109036834981;[AKT1]
GO:0006367;transcription initiation from RNA polymerase II promoter;9.0;1.0;0.896240625180289;9.628524252492122;477.15162764714074;4.629579150867016;0.015969835568764485;0.6329975182530758;[CCNH, NR3C2, NRBP1, MAZ, NR1H2, GTF2H1]
GO:0007214;gamma-aminobutyric acid signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.976932752798508;6.558197802812269;9.028936615729279E-4;0.6585068532133508;[GNAI2]
GO:0009749;response to glucose;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;32.95598622603122;4.917261223318797;0.001103007200523252;0.6023883328937558;[TGFB1]
GO:0010975;regulation of neuron projection development;8.0;0.5673924682959377;0.6586962341479689;8.404748820870006;84.29486529122617;3.652390236786265;0.0028212732808438556;0.5617834065627654;[AKT1, EZH2, TNR, DNM2]
GO:1900182;positive regulation of protein localization to nucleus;7.0;0.8436909121759173;0.7727648213451592;9.36615998802463;74.62336946219564;5.446340287394138;0.0024975770192273523;0.6294454608352614;[CDH1, AKT1, TGFB1, JUP]
GO:0060271;cilium assembly;6.0;0.8653626801206646;0.7558016526504768;9.405380701177911;137.68250629835126;4.347727998726029;0.00460810957959482;0.5454633246350222;[FLNA]
GO:0060395;SMAD protein signal transduction;5.0;1.0;0.7902410118609202;9.628524252492122;23.17027026302992;5.734022359845919;7.75488093814194E-4;0.5834791820027497;[TGFB1]
GO:0038061;NIK/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;6.8867018697843045;8.845336528452411E-4;0.6753065664753021;[AKT1]
GO:0038180;nerve growth factor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;27.195621953761602;7.292166977892469;9.102129923216596E-4;0.7238411236270654;[CORO1A]
GO:0048298;positive regulation of isotype switching to IgA isotypes;11.0;1.0;0.9324289523296623;9.628524252492122;1407.9016349495496;8.16763571524637;0.04712120069255247;0.8501222226412654;[TGFB1]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[EHMT2, AKT1, EZH2, MMP12, FLNA, GMNN, E2F7, HMGA1, AES, NR1H2, TLE4, MAP2K2, CNOT3, RFC1, PPP2R1A, IFNA2, XPO1, ARID4A, TGFB1, CBX4, MEIS2]
GO:0007219;Notch signaling pathway;6.0;0.7763722522362496;0.7113064387082693;8.866384200445225;26.50247477320489;4.99795013456894;8.87013979980389E-4;0.5787157149004503;[TGFB1, KRT19]
GO:0010867;positive regulation of triglyceride biosynthetic process;8.0;1.0;0.875;9.628524252492122;585.9051526913918;7.292166977892469;0.019609718180177402;0.747921758369865;[NR1H2]
GO:0010628;positive regulation of gene expression;6.0;0.4705935272257725;0.5584170762030307;6.666693530613812;58.797024432214236;2.2471302570788807;0.001967883493859682;0.43803865843940215;[AKT1, JUP, MMP12, ATAD2, E2F7, CCNH, HMGA1, NUP62, RAN, EHF, NUP85, EPCAM, NR1H2, GTF2H1, CDH3, CDH1, MAP2K2, RFC1, IFNA2, PRL, RHOG, ARID4A, HGS, TGFB1, DNM2, MEIS2]
GO:0010748;negative regulation of plasma membrane long-chain fatty acid transport;9.0;1.0;0.896240625180289;9.628524252492122;652.3932031735304;8.390779266560578;0.02183501339445399;0.8253454670833372;[AKT1]
GO:0010742;macrophage derived foam cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;21.75937296335754;7.8311634786251565;7.282666309192915E-4;0.6907270763441554;[TGFB1]
GO:0031663;lipopolysaccharide-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;6.343086423195323;8.87013979980389E-4;0.647506047256038;[AKT1, TGFB1]
GO:0010745;negative regulation of macrophage derived foam cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;114.21841186311113;7.212124270218933;0.0038227874551613377;0.6919486831672181;[NR1H2]
GO:0018105;peptidyl-serine phosphorylation;9.0;0.7369933605727446;0.7647373054666613;9.207310787415818;338.73676479787366;4.61801832846594;0.011337214674488616;0.6324062972578516;[, AKT1, MAP2K2, MAP4K1, PKN1]
GO:0030212;hyaluronan metabolic process;7.0;0.8933024483968273;0.7975705894556142;9.510741216835738;101.21806367924876;6.280566066213989;0.0033876775010012305;0.6721078059595746;[TGFB1, AKT1]
GO:0010862;positive regulation of pathway-restricted SMAD protein phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;1012.5567145242198;5.905872616772578;0.033889361993245395;0.7172676121338334;[TGFB1]
GO:0018107;peptidyl-threonine phosphorylation;9.0;0.7671156992804218;0.7797984748205;9.305750860229072;337.99482745314367;5.395046993006588;0.011312382699260763;0.6721435792979885;[AKT1, PKN1]
GO:0030214;hyaluronan catabolic process;8.0;1.0;0.875;9.628524252492122;501.2795327383162;6.8867018697843045;0.01677737483846132;0.7271862538851576;[TGFB1]
GO:0030335;positive regulation of cell migration;7.0;0.5846489169746516;0.6432438237445264;8.22453031427283;157.26390226612122;3.6656062881777913;0.005263481280523835;0.5383786413027378;[AKT1, ACTN4, PFN1, GNAI2, FLNA, CORO1A, TGFB1, LAMC2]
GO:0061035;regulation of cartilage development;5.0;0.7043150770688792;0.6423985503953599;8.781226392104918;27.37613670804801;5.6339389012889365;9.162546586948941E-4;0.5783609092777888;[TGFB1, POR]
GO:0045907;positive regulation of vasoconstriction;8.0;0.8933024483968273;0.8216512241984136;9.57973408832269;103.52331479149503;6.280566066213989;0.003464832181136806;0.6961884407023742;[AKT1]
GO:0006468;protein phosphorylation;7.0;0.5708408884191841;0.6363398094667926;8.175090588534603;177.75756772840523;2.970244267288293;0.005949385820444992;0.5028177952168079;[, AKT1, CIT, GTF2H1, PKN1, FGF5, MAP2K2, NRBP1, MELK, PKMYT1, CCNH, SPTAN1, MAP4K1, TGFB1, WEE1]
GO:0043602;nitrate catabolic process;6.0;1.0;0.8231203125901445;9.628524252492122;115.71498495965714;9.777073627680469;0.0038728764098743896;0.8231203125901445;[POR]
GO:0010718;positive regulation of epithelial to mesenchymal transition;6.0;0.811012628672052;0.7286266269261705;9.377209824211215;170.70262580884207;5.9928839937622085;0.005713263263432726;0.6295966787287501;[TGFB1, EZH2]
GO:0031659;positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle;13.0;1.0;0.9625549647676366;9.628524252492122;3325.2743974982595;7.8311634786251565;0.11129394153160196;0.8630410292508717;[AKT1]
GO:0032869;cellular response to insulin stimulus;8.0;1.0;0.875;9.628524252492122;462.69925393661634;5.334422371190153;0.015486127626965131;0.6478026081386739;[AKT1]
GO:0031536;positive regulation of exit from mitosis;9.0;1.0;0.896240625180289;9.628524252492122;562.0425168150831;8.16763571524637;0.018811057232375368;0.8139338954918922;[TGFB1]
GO:0097421;liver regeneration;6.0;1.0;0.8231203125901445;9.628524252492122;47.21654787453615;6.250713103064308;0.0015802953652264606;0.6427820713687392;[PCNA, TGFB1, EZH2]
GO:0010716;negative regulation of extracellular matrix disassembly;7.0;1.0;0.8509193652572005;9.628524252492122;86.13995449886744;8.390779266560578;0.002883026756151129;0.7800242071602487;[TGFB1]
GO:0032740;positive regulation of interleukin-17 production;6.0;0.8653626801206646;0.7558016526504768;9.427853557029971;65.23665507211369;7.212124270218933;0.002183412136085803;0.6919486831672181;[TGFB1]
GO:0060192;negative regulation of lipase activity;6.0;0.8259837884571596;0.7361122068187242;9.260799472366804;49.94359093049245;7.069023426578259;0.0016715670421299067;0.6846304993685643;[POR]
GO:0060071;Wnt signaling pathway, planar cell polarity pathway;9.0;0.7436939687323844;0.7680876095464813;9.094441766561864;99.0414819593438;5.825829909099042;0.0033148292696323837;0.694173837660411;[AP2M1, PFN1]
GO:0031532;actin cytoskeleton reorganization;6.0;1.0;0.8231203125901445;9.628524252492122;32.01253927882412;5.788089581116195;0.001071430880247358;0.6191234829421188;[FLNA]
GO:0007565;female pregnancy;3.0;1.0;0.6981203125901445;9.628524252492122;32.8060485501291;5.299736813202263;0.0010979889214459554;0.4691490996802742;[PRL, TGFB1, CLDN4]
GO:0006355;regulation of transcription, DNA-templated;9.0;0.4043225613388953;0.5984019058497367;6.838723401371219;245.35026186902695;1.5478292109445575;0.008211652463856259;0.4753966830094131;[NUP107, AKT1, JUP, MMP12, ATAD2, PKN1, GMNN, E2F7, FBXO5, PCNA, NR3C2, NUP133, NUP85, ZNF367, EPCAM, NR1H2, TLE4, MAP2K2, CCDC22, RFC1, PPP2R1A, IFNA2, PRL, XPO1, MLF2, CBX4, DNM2, EHMT2, EZH2, FLNA, MAZ, CCNH, HMGA1, NUP62, NUP35, RAN, EHF, HOXA9, CDC6, BRD2, AES, GTF2H1, CDH1, CNOT3, PFN1, RHOG, ARID4A, TGFB1, MEIS2]
GO:0006357;regulation of transcription by RNA polymerase II;10.0;0.43649654099988644;0.6334892823608635;7.109131426632953;248.56913769389934;1.8913682364374496;0.008319385340914571;0.5119656714299493;[EHMT2, AKT1, JUP, EZH2, MMP12, ATAD2, PKN1, MAZ, E2F7, CCNH, NR3C2, HMGA1, EHF, HOXA9, ZNF367, BRD2, AES, EPCAM, NR1H2, GTF2H1, TLE4, RFC1, PFN1, PRL, XPO1, ARID4A, TGFB1, CBX4, MEIS2]
GO:0030316;osteoclast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.510741216835738;47.07409398820286;6.375876246018314;0.0015755275618510598;0.6491829203200885;[TGFB1]
GO:0051232;meiotic spindle elongation;4.0;1.0;0.75;9.628524252492122;45.03457221597044;9.777073627680469;0.0015072666035848682;0.75;[PPP2R1A]
GO:0031641;regulation of myelination;6.0;0.8933024483968273;0.7697715367885581;9.405380701177911;42.055147161688105;6.250713103064308;0.001407547928326502;0.6427820713687392;[AKT1]
GO:0007253;cytoplasmic sequestering of NF-kappaB;13.0;1.0;0.9625549647676366;9.628524252492122;578.6196231821564;7.8311634786251565;0.019365878064054164;0.8630410292508717;[CCDC22]
GO:0032570;response to progesterone;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;105.99106082751567;6.166155715036245;0.0035474254201351726;0.6384578026126634;[TGFB1, CLDN4]
GO:0051091;positive regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.431813958246067;277.8307104044464;4.2636448815154875;0.00929874384583087;0.650471949850128;[AKT1, TGFB1, JUP]
GO:0051092;positive regulation of NF-kappaB transcription factor activity;12.0;0.9326813400603323;0.9144609826203107;9.587702257971866;279.4401483168805;4.8283137373023015;0.009352610284359957;0.6950405016553352;[TGFB1]
GO:0009437;carnitine metabolic process;5.0;0.8653626801206646;0.7229223519212526;9.36615998802463;68.6706074773741;7.138016298065211;0.002298343432733347;0.6552794972956795;[POR]
GO:0007016;cytoskeletal anchoring at plasma membrane;6.0;1.0;0.8231203125901445;9.628524252492122;66.89368938276097;7.474488534686424;0.002238871583229107;0.7053660038532718;[JUP, TLN1]
GO:0018393;internal peptidyl-lysine acetylation;10.0;0.6799073451904818;0.7551946844561612;8.959474623511237;469.91674389418733;5.104244793218563;0.015727690520525785;0.6762723279577749;[POR]
GO:0070723;response to cholesterol;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;80.91680144162417;6.686031174322154;0.002708212523857764;0.665044257777226;[OSBPL7, TGFB1]
GO:0046628;positive regulation of insulin receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;293.6040497598144;7.069023426578259;0.009826663318971241;0.7124295520356204;[GNAI2]
GO:0065003;protein-containing complex assembly;4.0;0.45485133202666184;0.4774256660133309;6.058991556010752;36.471478728154885;2.4440506132939883;0.0012206675708314864;0.3749888620238313;[, NUP107, CLDN3, JUP, ARHGAP6, GMNN, CCNH, FBXO5, H1FX, HMGA1, NASP, NUP62, NUP54, NUP205, BRD2, GTF2H1, TLE4, MCM2, RAD51, PPP2R1A, TLN1, KNTC1, TGFB1, DNM2, HIST1H2BK]
GO:0007143;female meiotic nuclear division;7.0;0.8933024483968273;0.7975705894556142;9.474373572664863;65.96656019186406;7.069023426578259;0.0022078414035718876;0.7124295520356204;[PPP2R1A]
GO:0090340;positive regulation of secretion of lysosomal enzymes;9.0;1.0;0.896240625180289;9.628524252492122;483.37920529406273;9.777073627680469;0.016178266988150954;0.896240625180289;[NR1H2]
GO:0046622;positive regulation of organ growth;6.0;0.811012628672052;0.7286266269261705;9.360260265897443;146.55654105553208;5.926926025970411;0.004905115536804883;0.6262235851885184;[AKT1]
GO:0008354;germ cell migration;5.0;0.9326813400603323;0.7565816818910864;9.510741216835738;40.540081573954176;7.57984905034425;0.0013568400465755524;0.6778748447945537;[TGFB1]
GO:0043113;receptor clustering;6.0;0.7671156992804218;0.7066781622303554;8.992535485772125;42.889232177334534;5.9928839937622085;0.0014354640031724087;0.6295966787287501;[FLNA]
GO:0043117;positive regulation of vascular permeability;6.0;1.0;0.8231203125901445;9.628524252492122;22.58320658440663;7.474488534686424;7.558396008136816E-4;0.7053660038532718;[TGFB1]
GO:0045662;negative regulation of myoblast differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;6.518977089658987;0.0038363580074348307;0.6565011041187423;[TGFB1]
GO:0070830;bicellular tight junction assembly;6.0;1.0;0.8231203125901445;9.628524252492122;56.140948375987016;6.280566066213989;0.001878987018571015;0.6443087532925187;[ACTN4, CLDN3]
GO:0001837;epithelial to mesenchymal transition;5.0;0.7508913569872202;0.6656866903545304;8.647694999480395;23.145667324477426;5.618190544320798;7.746646556020492E-4;0.5775555375700647;[TGFB1]
GO:1990418;response to insulin-like growth factor stimulus;5.0;1.0;0.7902410118609202;9.628524252492122;25.223505691001428;8.67846133901236;8.44208035796484E-4;0.7340579283277371;[AKT1]
GO:0100002;negative regulation of protein kinase activity by protein phosphorylation;11.0;1.0;0.9324289523296623;9.628524252492122;1279.8925717232403;9.777073627680469;0.04283685254704534;0.9324289523296623;[AKT1]
GO:0032436;positive regulation of proteasomal ubiquitin-dependent protein catabolic process;11.0;0.8259837884571596;0.845420846558242;9.498471124243924;3778.5456327194074;5.334422371190153;0.12646452185682636;0.705231560468336;[AKT1]
GO:0034614;cellular response to reactive oxygen species;5.0;0.7671156992804218;0.6737988615011312;9.197741336399668;144.094088465717;5.076593261888053;0.004822699464687224;0.5498582273596049;[AKT1, DNM2, PCNA, EZH2]
GO:0090108;positive regulation of high-density lipoprotein particle assembly;7.0;1.0;0.8509193652572005;9.628524252492122;180.03201214260082;9.777073627680469;0.0060255094281210396;0.8509193652572005;[NR1H2]
GO:0045429;positive regulation of nitric oxide biosynthetic process;8.0;1.0;0.875;9.628524252492122;658.6394256443023;6.166155715036245;0.02204406883931546;0.6903374900225189;[AKT1, DNM2]
GO:0097191;extrinsic apoptotic signaling pathway;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;51.05903939735586;5.277263957350204;0.0017089000984773794;0.5929998367869052;[TGFB1]
GO:0043123;positive regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.11083947336738;4.629579150867016;0.008002824611389124;0.6117568930727868;[AKT1, CCDC22, NUP62, FLNA]
GO:0045542;positive regulation of cholesterol biosynthetic process;10.0;1.0;0.9152410118609203;9.628524252492122;664.4438225279273;8.16763571524637;0.022238336779392343;0.8329342821725234;[POR]
GO:0043488;regulation of mRNA stability;9.0;0.7436939687323844;0.7680876095464813;9.240758721483358;282.23354693635815;4.989581884898423;0.009446102822258332;0.6514080748132811;[XPO1, AKT1]
GO:0043124;negative regulation of I-kappaB kinase/NF-kappaB signaling;8.0;0.8933024483968273;0.8216512241984136;9.517298617381897;239.487551390376;6.063501560976162;0.008015432820232688;0.6850877518099798;[CCDC22]
GO:0060709;glycogen cell differentiation involved in embryonic placenta development;5.0;1.0;0.7902410118609202;9.628524252492122;42.294635617598914;9.777073627680469;0.0014155633914202197;0.7902410118609202;[AKT1]
GO:0043491;protein kinase B signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;6.250713103064308;8.845336528452411E-4;0.6427820713687392;[TGFB1, TSC2, AKT1]
GO:0007229;integrin-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;5.311165509025885;8.87013979980389E-4;0.5947335637161829;[ITGB4, ITGB6, TLN1, ZYX]
GO:0031339;negative regulation of vesicle fusion;7.0;0.8436909121759173;0.7727648213451592;9.392135474427892;149.70009243093662;7.9853141584524145;0.00501032737232711;0.7592887026755414;[CORO1A]
GO:0035815;positive regulation of renal sodium excretion;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;135.61946749691032;7.069023426578259;0.004539061527524972;0.7365101867784198;[GNAI2]
GO:0019221;cytokine-mediated signaling pathway;6.0;0.6039883530135606;0.6251144890969248;7.604142487995313;26.50247477320489;3.309374901576116;8.87013979980389E-4;0.49236189895841853;[AKT1, IFNA14, IFNA16, IFNA10, IFNA21, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, TGFB1]
GO:0043011;myeloid dendritic cell differentiation;6.0;0.8933024483968273;0.7697715367885581;9.4949928598676;91.1712242271392;6.8867018697843045;0.003051418826107602;0.6753065664753021;[TGFB1]
GO:0060828;regulation of canonical Wnt signaling pathway;7.0;0.6954798709641801;0.6986593007392905;8.83001655627435;44.04846258837617;4.37439624580819;0.0014742624017903352;0.5746261926980603;[TLE4, JUP, AES, PPP1CA]
GO:0045792;negative regulation of cell size;6.0;1.0;0.8231203125901445;9.628524252492122;29.63014819255531;7.474488534686424;9.916943946027175E-4;0.7053660038532718;[AKT1]
GO:0010875;positive regulation of cholesterol efflux;9.0;1.0;0.896240625180289;9.628524252492122;184.0088741739662;7.069023426578259;0.0061586114213673755;0.757750811958709;[NR1H2]
GO:0016197;endosomal transport;5.0;0.7090535922965819;0.6447678080092112;8.817594036275793;47.18803257139101;4.463867648638682;0.0015793409836922997;0.5185234110033771;[HGS]
GO:0010634;positive regulation of epithelial cell migration;8.0;0.7866048967936545;0.7683024483968273;9.383401794459138;242.52723865374625;4.901876304479318;0.00811716841739676;0.6256821821716325;[AKT1, PFN1, TGFB1]
GO:0031334;positive regulation of protein complex assembly;6.0;0.612588685250814;0.6294146552155515;8.094593892566166;105.21570715161425;4.251620688548686;0.0035214750303757575;0.5405483923231058;[PFN1, TGFB1, BIK, NR1H2, GTF2H1]
GO:0035810;positive regulation of urine volume;5.0;0.9326813400603323;0.7565816818910864;9.510741216835738;23.90496242438734;7.138016298065211;8.000775792748091E-4;0.6552794972956795;[GNAI2]
GO:0090201;negative regulation of release of cytochrome c from mitochondria;9.0;1.0;0.896240625180289;9.628524252492122;472.8116675549172;6.943860283624253;0.015824581010188264;0.7513499630073597;[AKT1]
GO:0032781;positive regulation of ATPase activity;6.0;0.7508913569872202;0.6985659910837546;8.781226392104918;51.416896668601964;5.8067817141283475;0.0017208772592953517;0.6200793994936333;[DNM2, PFN1]
GO:0006275;regulation of DNA replication;7.0;0.6144040707577935;0.6581214006360973;8.623002386890024;150.73814970462044;5.142344639450834;0.005045070215086414;0.6138991092621975;[EHMT2, GMNN, PPP2R1A, SMC1A, PCNA, E2F7, CDC6]
GO:0007249;I-kappaB kinase/NF-kappaB signaling;6.0;1.0;0.8231203125901445;9.628524252492122;26.42836680105094;5.602686357784832;8.845336528452411E-4;0.6096419534788213;[AKT1]
GO:0046889;positive regulation of lipid biosynthetic process;7.0;0.6056485694559711;0.6537436499851861;8.181605269555796;116.24437576905906;5.572381008289503;0.003890594643844275;0.6358911891633434;[AKT1, NR1H2, POR]
GO:0032417;positive regulation of sodium:proton antiporter activity;11.0;1.0;0.9324289523296623;9.628524252492122;842.887139998128;8.390779266560578;0.028210674026560526;0.8615337942327104;[ACTN4]
GO:1990314;cellular response to insulin-like growth factor stimulus;8.0;1.0;0.875;9.628524252492122;388.66587636398185;7.57984905034425;0.013008297105323164;0.7626338329336335;[TGFB1]
GO:0001933;negative regulation of protein phosphorylation;9.0;0.6056485694559711;0.6990649099082746;8.75603614327636;664.693789818838;3.7392027077583316;0.02224670295966317;0.5874636255457587;[PPP2R1A, AKT1, SFN, PKN1, TSC2, TGFB1, NUP62]
GO:0010765;positive regulation of sodium ion transport;8.0;0.7586651285174919;0.754332564258746;9.0306872517365;68.46428617144959;6.375876246018314;0.0022914380443011736;0.701062607729944;[ACTN4, DNM2, AKT1]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CORO1A, NUP85, TGFB1, EPCAM]
GO:0010887;negative regulation of cholesterol storage;7.0;1.0;0.8509193652572005;9.628524252492122;69.52771242693282;7.8311634786251565;0.002327029964050703;0.7514054297404357;[NR1H2]
GO:0030595;leukocyte chemotaxis;6.0;0.6873818243518346;0.6668112247660618;8.768322987269011;62.06300720445581;4.857092701852345;0.002077192998052941;0.5715122592407831;[CORO1A, NUP85]
GO:0030111;regulation of Wnt signaling pathway;6.0;0.5902001590945054;0.6182203921373972;7.99439372746765;41.8512380110395;4.069963362931594;0.0014007232725606145;0.5312584282431182;[PPP2R1A, TLE4, TSC2, JUP, AES, PPP1CA]
GO:0001938;positive regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.3065775231622;5.277263957350204;0.0029220725788817177;0.6207988894539612;[AKT1]
GO:0035924;cellular response to vascular endothelial growth factor stimulus;6.0;1.0;0.8231203125901445;9.628524252492122;62.59148538135601;6.599019797332524;0.00209488068703431;0.6605944919115335;[AKT1]
GO:0010763;positive regulation of fibroblast migration;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;201.49065414776382;7.379178354882098;0.006743710864509851;0.7523715242355574;[TGFB1, AKT1]
GO:0010884;positive regulation of lipid storage;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;46.19953359410991;6.686031174322154;0.0015462568125140237;0.665044257777226;[NR1H2]
GO:0010642;negative regulation of platelet-derived growth factor receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.503361109538115;188.1075192762445;7.212124270218933;0.006295789384399518;0.7197477358342742;[HGS]
GO:0033864;positive regulation of NAD(P)H oxidase activity;6.0;1.0;0.8231203125901445;9.628524252492122;95.10874301741602;7.8311634786251565;0.0031832040364813217;0.7236063770733796;[GNAI2]
GO:0033622;integrin activation;5.0;1.0;0.7902410118609202;9.628524252492122;40.42272244673708;7.57984905034425;0.0013529121422039536;0.6778748447945537;[TLN1]
GO:0007050;cell cycle arrest;6.0;0.811012628672052;0.7286266269261705;9.292052015870908;55.61614271062087;4.7664383335842135;0.0018614222452456451;0.5668761906316916;[TGFB1]
GO:0008380;RNA splicing;8.0;0.7248374789738407;0.7374187394869203;9.182237149863703;117.47952805794706;3.8501476017100584;0.003931934079388465;0.5718967274016261;[PPP2R1A, ACIN1]
GO:0007173;epidermal growth factor receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.040737587590003;32.38857880465376;5.788089581116195;0.0010840165847632744;0.6922437955322635;[AKT1, TGFB1]
GO:0007179;transforming growth factor beta receptor signaling pathway;8.0;0.7586651285174919;0.754332564258746;9.05316010758856;29.903672154863813;5.2552850506314295;0.0010008489954655988;0.6437555218850388;[TGFB1, ZYX]
GO:0045600;positive regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.26328322821418;5.71663061713405;0.00382428925936973;0.6154690682008903;[AKT1]
GO:0043666;regulation of phosphoprotein phosphatase activity;9.0;0.7436939687323844;0.7680876095464813;9.328419660041783;158.30216566976694;5.058574756385375;0.005298231022267458;0.6549363734696205;[PPP2R1A, GNAI2]
GO:0045725;positive regulation of glycogen biosynthetic process;10.0;1.0;0.9152410118609203;9.628524252492122;1082.4256827352704;7.004484905440688;0.036227813481280256;0.7734506956670166;[AKT1]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[EZH2, ARHGAP6, RHOG, RANBP1, SIPA1, TSC2, ACAP1]
GO:0045723;positive regulation of fatty acid biosynthetic process;8.0;0.7980440201809971;0.7740220100904985;9.446202695698167;668.0274522036976;7.004484905440688;0.022358277639583056;0.7332096838060964;[NR1H2]
GO:0019049;evasion or tolerance of host defenses by virus;9.0;0.660418147677249;0.7264496990189135;8.890925309361343;177.3716437189982;8.390779266560578;0.005936469291159198;0.8253454670833372;[TGFB1]
GO:0031397;negative regulation of protein ubiquitination;10.0;0.7508913569872202;0.7906866903545304;9.372590878354922;529.4632463014641;5.572381008289503;0.01772065836772442;0.7002128357670632;[AKT1, FBXO5]
GO:0010575;positive regulation of vascular endothelial growth factor production;6.0;1.0;0.8231203125901445;9.628524252492122;64.54350789155374;6.481236761676141;0.002160213123744424;0.6545710619905948;[TGFB1]
GO:0032369;negative regulation of lipid transport;6.0;0.6281612110245125;0.6372009181024008;8.242229891372231;82.88956312991112;6.558197802812269;0.0027742390821944756;0.6585068532133508;[NR1H2, AKT1]
GO:0007182;common-partner SMAD protein phosphorylation;8.0;1.0;0.875;9.628524252492122;180.75330000196035;7.9853141584524145;0.006049650283656873;0.7833693374183408;[TGFB1]
GO:0007183;SMAD protein complex assembly;6.0;1.0;0.8231203125901445;9.628524252492122;44.51706700895919;7.8311634786251565;0.0014899461700306506;0.7236063770733796;[TGFB1]
GO:0007186;G-protein coupled receptor signaling pathway;5.0;0.5508212674310002;0.5656516455764204;7.20077601654407;23.17027026302992;2.605416804911955;7.75488093814194E-4;0.4234821484283897;[AKT1, RHOG, GNAI2, FLNA, LHCGR, DGKZ, GNB2]
GO:0043552;positive regulation of phosphatidylinositol 3-kinase activity;11.0;0.9326813400603323;0.8987696223598284;9.597752593825367;732.6859750532908;6.375876246018314;0.024522340210466318;0.7584915600596062;[TGFB1]
GO:0043312;neutrophil degranulation;9.0;1.0;0.896240625180289;9.628524252492122;132.80263134205524;3.603287523778533;0.004444784556409926;0.5805129167163294;[JUP, APEH, STXBP2, NBEAL2, SPTAN1, RHOG]
GO:0043433;negative regulation of DNA binding transcription factor activity;11.0;0.811012628672052;0.8379352666656883;9.468181602416943;278.0076986152632;4.753193106834193;0.00930466748196786;0.6755074688592472;[FLNA, CCDC22, EZH2]
GO:0042102;positive regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;564.8543510249671;5.212725436212633;0.018905166792893686;0.6628196464047262;[CORO1A]
GO:0007189;adenylate cyclase-activating G-protein coupled receptor signaling pathway;9.0;0.7763722522362496;0.7844267512984139;9.249034630787218;56.871035456649615;5.192106149009898;0.0019034223761250782;0.6617651750982834;[GNAI2, LHCGR]
GO:2000727;positive regulation of cardiac muscle cell differentiation;9.0;0.8436909121759173;0.8180860812682478;9.4949928598676;667.9527156383532;6.8867018697843045;0.02235577627399952;0.7484268790654467;[TGFB1]
GO:0019395;fatty acid oxidation;8.0;0.7763722522362496;0.7631861261181248;9.283683766200392;147.7937623067202;5.446340287394138;0.004946524218655313;0.6535260955780609;[POR]
GO:0032355;response to estradiol;5.0;0.9326813400603323;0.7565816818910864;9.523163736834295;74.25476231829794;4.940791720728991;0.0024852400698459885;0.542913330229313;[PCNA, TGFB1, EZH2]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[FGF5, IFNA14, IFNA16, IFNA10, IFNA21, TGFB1, IFNA5, IFNA4, IFNA7, IFNA2, PRL, IFNA8]
GO:0032233;positive regulation of actin filament bundle assembly;10.0;0.8933024483968273;0.861892236059334;9.533214072687796;256.92976895603965;5.734022359845919;0.008599208145178776;0.7084791820027498;[FLNA, PFN1]
GO:0090307;mitotic spindle assembly;8.0;1.0;0.875;9.628524252492122;186.05212215721153;6.193554689224359;0.006226997092562797;0.6917386748366816;[FLNA]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[CORO1A, RHOG]
GO:1905000;regulation of membrane repolarization during atrial cardiac muscle cell action potential;11.0;0.8933024483968273;0.8790801765280758;9.571365838652174;341.26330238295816;9.777073627680469;0.01142177561372519;0.9324289523296623;[FLNA]
GO:0030050;vesicle transport along actin filament;7.0;0.9326813400603323;0.8172600352873667;9.574457031221845;136.86115064074093;7.697632086000634;0.004580619544906703;0.7445766281117727;[ACTN4]
GO:0045742;positive regulation of epidermal growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.417215158824915;233.1839134473908;6.280566066213989;0.0078044557311868065;0.6961884407023742;[NUP62, AKT1]
GO:0043320;natural killer cell degranulation;9.0;1.0;0.896240625180289;9.628524252492122;133.05394577034187;8.16763571524637;0.004453195824156379;0.8139338954918922;[CORO1A]
GO:0045861;negative regulation of proteolysis;8.0;0.612588685250814;0.681294342625407;8.712233520617966;337.1756827485802;3.92774884773361;0.011284966663181396;0.5758652587320976;[AKT1, POR, SPINT1, SFN, NR1H2]
GO:0043687;post-translational protein modification;7.0;0.6467165523344657;0.6742776414244334;8.507933057105237;151.15475272427284;3.8799197600437285;0.005059013543235805;0.5493386422205575;[SKP2, NUCB1, CCDC22, UBE2M]
GO:0042482;positive regulation of odontogenesis;7.0;0.8436909121759173;0.7727648213451592;9.474373572664863;103.86878039186215;7.379178354882098;0.0034763946038822383;0.728290889492758;[TGFB1]
GO:0001845;phagolysosome assembly;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;81.92137458931388;8.16763571524637;0.002741834683053802;0.7686126355688037;[CORO1A]
GO:0007281;germ cell development;4.0;0.8653626801206646;0.6826813400603323;9.34084218004034;71.68419734523428;4.759793790865545;0.0023992055735558276;0.4934160758179115;[AKT1]
GO:1903077;negative regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.4949928598676;218.53196919702376;6.686031174322154;0.007314068343020746;0.7169239451870815;[TGFB1, AP2M1]
GO:0035970;peptidyl-threonine dephosphorylation;8.0;1.0;0.875;9.628524252492122;179.24922260518233;7.004484905440688;0.005999310166768488;0.7332096838060964;[PPP1CA]
GO:0007043;cell-cell junction assembly;5.0;0.7508913569872202;0.6656866903545304;8.817594036275793;53.94372379865016;5.16195311083921;0.0018054478893412883;0.554223534004606;[CDH3, CDH1, JUP, LSR, ACTN4, CLDN3, TLN1]
GO:0007044;cell-substrate junction assembly;5.0;0.8653626801206646;0.7229223519212526;9.377209824211215;36.1037539480283;6.088194173566533;0.0012083601533714658;0.6015915450270957;[LAMB3, ITGB4, LAMA3, LAMC2, ARHGAP6, TLN1]
GO:0030163;protein catabolic process;5.0;0.6347111282356054;0.607596575978723;8.35223078658656;135.66522553384723;3.7109655375767217;0.004540593007841691;0.48001996203013964;[, AKT1, SKP2, AP2M1]
GO:1903078;positive regulation of protein localization to plasma membrane;8.0;0.8436909121759173;0.7968454560879586;9.434368238051164;218.50214452761784;5.845247994956144;0.00731307013817619;0.6739262542938873;[AKT1, RHOG]
GO:0001973;adenosine receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;54.8657018871206;7.57984905034425;0.0018363056662359847;0.7626338329336335;[GNAI2]
GO:0042130;negative regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;581.9323154417883;5.734022359845919;0.01947675089275457;0.6894787953221185;[TGFB1]
GO:0045880;positive regulation of smoothened signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.503361109538115;187.6437959822434;6.343086423195323;0.006280268983073171;0.6753050999230941;[POR]
GO:0032332;positive regulation of chondrocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.567899630675686;229.711107350086;6.832634648514029;0.007688224036432589;0.7003406189322132;[POR]
GO:0030279;negative regulation of ossification;5.0;0.8436909121759173;0.712086467948879;9.377209824211215;41.83246312675316;5.500407508664414;0.0014000948940798496;0.571532107649126;[TGFB1]
GO:0071901;negative regulation of protein serine/threonine kinase activity;11.0;0.7369933605727446;0.8009256326160346;9.385578073881732;1262.8536775520981;4.8942717050940985;0.0422665760931464;0.6827222349350845;[PPP2R1A, NUP62, AKT1, SFN]
GO:0030036;actin cytoskeleton organization;5.0;0.6347111282356054;0.607596575978723;8.048073876931273;29.6146440060229;3.9779809732199434;9.911754834323397E-4;0.49367514382642164;[TLN1, PFN1, CORO1A, RHOG, FLNA, KRT19, ZYX]
GO:0007093;mitotic cell cycle checkpoint;7.0;0.7140352122741334;0.7079369713942671;9.0094850440859;132.2042645947957;5.142344639450834;0.0044247577598742595;0.6138991092621975;[KNTC1, TGFB1, CDC6, WEE1]
GO:0060762;regulation of branching involved in mammary gland duct morphogenesis;6.0;0.8933024483968273;0.7697715367885581;9.446202695698167;93.99544391330774;8.16763571524637;0.0031459429173709623;0.7408135829017477;[TGFB1]
GO:1903800;positive regulation of production of miRNAs involved in gene silencing by miRNA;10.0;0.8933024483968273;0.861892236059334;9.566003895510788;702.6387462348895;7.697632086000634;0.023516686502664728;0.8088982747154926;[TGFB1, MAP2K2]
GO:0048754;branching morphogenesis of an epithelial tube;6.0;0.7436939687323844;0.6949672969563367;8.8813098506619;51.7127811195946;4.956792062075433;0.0017307802455913577;0.5766108891590862;[TGFB1, PPP1CA]
GO:0060644;mammary gland epithelial cell differentiation;5.0;0.8259837884571596;0.7032329060895001;9.117698628726131;24.20171999872632;6.943860283624253;8.100097882234571E-4;0.6453503496879909;[AKT1]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[AKT1, ACTN4, CLDN3, TGFB1]
GO:0048642;negative regulation of skeletal muscle tissue development;8.0;0.7866048967936545;0.7683024483968273;9.310070521373587;215.71554513694034;7.212124270218933;0.007219805164346847;0.7438283705770736;[TGFB1]
GO:0032287;peripheral nervous system myelin maintenance;6.0;1.0;0.8231203125901445;9.628524252492122;21.34652774794371;7.8311634786251565;7.144490730959624E-4;0.7236063770733796;[AKT1]
GO:0050714;positive regulation of protein secretion;8.0;0.6467165523344657;0.6983582761672329;8.730582659286164;381.48337166918856;4.304802954008995;0.01276790513702299;0.5951478232618299;[TGFB1, MMP12, NR1H2]
GO:0035556;intracellular signal transduction;5.0;0.5140152493238541;0.5472486365228473;6.9204740513899115;23.17027026302992;2.4005655013542495;7.75488093814194E-4;0.41300604323788886;[AKT1, SFN, ARHGAP6, PKN1, E2F7, SH2B1, SPTAN1, PCNA, GNAI2, EPS8L1, STMN1, CIT, FGF5, LHCGR, MAP2K2, DGKZ, NRBP1, MELK, CNOT3, PPP2R1A, PRL, MAP4K1, RHOG, SIPA1, TSC2, TGFB1]
GO:0033138;positive regulation of peptidyl-serine phosphorylation;10.0;0.9326813400603323;0.8815816818910864;9.59573442966913;778.6672313762616;5.152100814396198;0.026061291479152104;0.6787196871063318;[IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, AKT1, IFNA14, IFNA16, IFNA10, IFNA21, TGFB1]
GO:0060751;branch elongation involved in mammary gland duct branching;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;21.218694376440094;9.777073627680469;7.101706051943016E-4;0.8231203125901445;[TGFB1]
GO:0090187;positive regulation of pancreatic juice secretion;7.0;0.8653626801206646;0.7836007053175329;9.517298617381897;141.80155240363064;9.083926447120524;0.004745970345837699;0.8154717862087246;[NR1H2]
GO:0090190;positive regulation of branching involved in ureteric bud morphogenesis;8.0;1.0;0.875;9.628524252492122;298.04283299406984;6.832634648514029;0.009975225399176214;0.7244212536750128;[TGFB1]
GO:0050727;regulation of inflammatory response;6.0;0.5272636092234699;0.5867521172018795;7.400047131651798;31.586589572713706;3.8007227183825356;0.00105717472691369;0.517489449159909;[ZYX]
GO:0035307;positive regulation of protein dephosphorylation;9.0;0.811012628672052;0.801746939516315;9.464221201200845;660.9024749708963;6.063501560976162;0.022119811063664396;0.706328376990269;[TGFB1]
GO:0071407;cellular response to organic cyclic compound;5.0;0.5310727365277519;0.5557773801247963;7.0299582842316;63.0333181336412;3.907776714546695;0.0021096684316296343;0.4900848947730398;[AKT1, JUP, EZH2, CDH1, OSBPL7, TGFB1, DNM2, RAD51]
GO:0010389;regulation of G2/M transition of mitotic cell cycle;8.0;0.7369933605727446;0.7434966802863723;8.986670366319727;58.92720908338202;4.74012102526684;0.001972240656975688;0.6174100096703167;[PPP2R1A, CDC6]
GO:0071526;semaphorin-plexin signaling pathway;6.0;0.811012628672052;0.7286266269261705;9.089527751759436;26.50247477320489;6.166155715036245;8.87013979980389E-4;0.6384578026126634;[FLNA]
GO:0032270;positive regulation of cellular protein metabolic process;7.0;0.47017759384120705;0.586008162177804;7.412950536487706;288.49227156764;2.455885070940991;0.00965557670318086;0.47651344199545814;[, AKT1, EZH2, PKN1, IFNA14, IFNA16, IFNA10, IFNA21, CCNH, GNAI2, CDC6, NR1H2, MAP2K2, OSBPL7, CCDC22, SKP2, IFNA5, IFNA4, IFNA7, IFNA2, IFNA8, MAP4K1, TGFB1]
GO:0007193;adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway;8.0;0.7866048967936545;0.7683024483968273;9.117698628726131;28.36322711391944;5.334422371190153;9.492916862557204E-4;0.6478026081386739;[GNAI2, FLNA]
GO:0007194;negative regulation of adenylate cyclase activity;12.0;0.8933024483968273;0.8947715367885583;9.589303539338841;6285.124034700197;6.481236761676141;0.21035744519701882;0.7795710619905949;[GNAI2]
GO:0031065;positive regulation of histone deacetylation;10.0;0.8933024483968273;0.861892236059334;9.571365838652174;1219.9035963218012;6.8867018697843045;0.04082907552693193;0.7674272657460779;[TGFB1]
GO:0008286;insulin receptor signaling pathway;8.0;0.8653626801206646;0.8076813400603323;9.34084218004034;31.002284443533863;5.346256828837156;0.0010376185600805164;0.6484078228531001;[AKT1]
GO:0008285;negative regulation of cell proliferation;5.0;0.5619039856592722;0.5711930046905564;7.31175452450612;43.614270733588945;3.2818080717434612;0.0014597303911579066;0.4580728292695636;[SPINT1, SFN, CDC6, PRL, PKN1, TSC2, HGS, TGFB1, HMGA1, NUP62, E2F7]
GO:0007195;adenylate cyclase-inhibiting dopamine receptor signaling pathway;9.0;1.0;0.896240625180289;9.628524252492122;58.23053162461359;7.474488534686424;0.0019489234893997154;0.7784863164434164;[FLNA]
GO:0090031;positive regulation of steroid hormone biosynthetic process;9.0;0.8436909121759173;0.8180860812682478;9.533214072687796;661.8667994737442;8.67846133901236;0.02215208613693901;0.8400575416471059;[POR]
GO:0001893;maternal placenta development;4.0;1.0;0.75;9.628524252492122;43.252245699280884;7.379178354882098;0.001447613739060994;0.6273715242355574;[AKT1]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[AKT1, SKP2, GNAI2]
GO:0071677;positive regulation of mononuclear cell migration;9.0;0.8933024483968273;0.8428918493787028;9.533214072687796;295.2864367703214;6.686031174322154;0.009882971298162901;0.7381645703673706;[TGFB1]
GO:0001649;osteoblast differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[AKT1]
GO:0034329;cell junction assembly;4.0;0.7140352122741334;0.6070176061370667;8.529911963824013;35.00514165935835;4.7018998124466425;0.0011715905887565515;0.49045537506922354;[ITGB4, LAMC2, ARHGAP6, CDH3, CDH1, LSR, ACTN4, CLDN3, TLN1, LAMA3, FLNA, JUP, LAMB3]
GO:0050731;positive regulation of peptidyl-tyrosine phosphorylation;10.0;0.7866048967936545;0.8085434602577476;9.446202695698167;779.3603785568229;4.60092389510664;0.02608449049149353;0.6505324738215158;[IFNA2, TGFB1]
GO:0032148;activation of protein kinase B activity;12.0;1.0;0.9481203125901445;9.628524252492122;1099.1709144601095;6.311337724880743;0.03678826131738048;0.770882417347765;[AKT1]
GO:0035655;interleukin-18-mediated signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;30.19135422731818;7.8311634786251565;0.00101047745553359;0.7514054297404357;[AKT1]
GO:0031295;T cell costimulation;9.0;0.9326813400603323;0.8625812952104552;9.587702257971866;354.8971974647038;5.845247994956144;0.011878089812402261;0.6951668794741764;[AKT1]
GO:0031293;membrane protein intracellular domain proteolysis;7.0;0.9326813400603323;0.8172600352873667;9.533214072687796;50.748517158788495;6.8867018697843045;0.0016985071986044009;0.7031056191423581;[TGFB1]
GO:0060416;response to growth hormone;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;74.03337757263446;7.138016298065211;0.0024778305216419678;0.7159578506919597;[AKT1]
GO:0061502;early endosome to recycling endosome transport;6.0;1.0;0.8231203125901445;9.628524252492122;50.18376484494501;9.083926447120524;0.001679605446904144;0.7876727335416686;[CORO1A]
GO:0048549;positive regulation of pinocytosis;8.0;0.9326813400603323;0.8413406700301662;9.56398573135455;174.47961519612048;8.390779266560578;0.005839675699155172;0.8041048419030481;[ACTN4]
GO:0048550;negative regulation of pinocytosis;8.0;0.9326813400603323;0.8413406700301662;9.56398573135455;174.57219107609745;8.16763571524637;0.005842774130545118;0.7926932703116032;[NR1H2]
GO:0001657;ureteric bud development;8.0;1.0;0.875;9.628524252492122;36.921511297847346;6.139487467954083;0.0012357297559360753;0.6889736746265369;[TGFB1, EPCAM]
GO:0071549;cellular response to dexamethasone stimulus;9.0;1.0;0.896240625180289;9.628524252492122;704.2721689024621;6.343086423195323;0.023571355689363423;0.7206263598461826;[TGFB1]
GO:0034394;protein localization to cell surface;5.0;1.0;0.7902410118609202;9.628524252492122;29.829169826127035;6.686031174322154;9.983554695705216E-4;0.6321649570480018;[FLNA]
GO:0042176;regulation of protein catabolic process;6.0;0.5945822691631375;0.6204114471717133;8.214830917184116;56.791667214012804;3.8826707934156186;0.001900765992470805;0.5216802775280761;[AKT1, XPO1, FLNA, HGS, OSBPL7, CCDC22]
GO:0046777;protein autophosphorylation;8.0;0.7763722522362496;0.7631861261181248;9.31486669363708;180.75330000196035;4.488806596985934;0.006049650283656873;0.604557778120715;[AKT1, MAP2K2, MELK, MAP4K1]
GO:0042177;negative regulation of protein catabolic process;7.0;0.7140352122741334;0.7079369713942671;9.105276108727574;231.8232476428224;5.040875179285974;0.007758915471227624;0.6087099563505541;[FLNA]
GO:0042059;negative regulation of epidermal growth factor receptor signaling pathway;8.0;0.8436909121759173;0.7968454560879586;9.417215158824915;234.05310184950287;6.113511981550823;0.00783354668478672;0.6876452870438905;[NUP62, HGS]
GO:0043149;stress fiber assembly;8.0;1.0;0.875;9.628524252492122;75.13737719114397;7.292166977892469;0.00251478039533833;0.747921758369865;[ZYX]
GO:0032091;negative regulation of protein binding;5.0;0.6997970393407541;0.6401395315312973;8.48339194818912;32.716075545242866;5.171903441692378;0.0010949776059428606;0.5547323943871747;[STMN1, AKT1, AES, PPP1CA]
GO:0043029;T cell homeostasis;7.0;1.0;0.8509193652572005;9.628524252492122;22.00128503895464;6.444869117505266;7.363632103827933E-4;0.6805102716434839;[TGFB1, CORO1A]
GO:2000679;positive regulation of transcription regulatory region DNA binding;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;47.96814533750694;6.641579411751319;0.0016054506559182917;0.6627709925721352;[TGFB1]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[AKT1, POR, SFN]
GO:0043153;entrainment of circadian clock by photoperiod;6.0;1.0;0.8231203125901445;9.628524252492122;32.762264927729;6.686031174322154;0.001096523523006926;0.665044257777226;[PPP1CA]
GO:0035357;peroxisome proliferator activated receptor signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;25.568165535828406;7.697632086000634;8.557434906291208E-4;0.7167775754447168;[ACTN4]
GO:0050805;negative regulation of synaptic transmission;7.0;0.6835726970475526;0.6927057137809769;8.781226392104918;101.84774727695553;5.6339389012889365;0.00340875244433803;0.6390392626740691;[GNAI2, TNR]
GO:0003420;regulation of growth plate cartilage chondrocyte proliferation;6.0;0.8653626801206646;0.7558016526504768;9.446202695698167;158.62121753476586;9.083926447120524;0.005308909401060936;0.7876727335416686;[POR]
GO:0046426;negative regulation of JAK-STAT cascade;9.0;0.9326813400603323;0.8625812952104552;9.577230958104572;286.97803335492995;5.845247994956144;0.009604896512927369;0.6951668794741764;[HGS, PPP2R1A]
GO:0060716;labyrinthine layer blood vessel development;5.0;1.0;0.7902410118609202;9.628524252492122;85.12843743852892;6.781341354126479;0.0028491721904478507;0.6370391240755715;[AKT1]
GO:0006809;nitric oxide biosynthetic process;6.0;1.0;0.8231203125901445;9.628524252492122;241.09966064176743;7.212124270218933;0.008069388666072628;0.6919486831672181;[AKT1]
GO:0032079;positive regulation of endodeoxyribonuclease activity;9.0;1.0;0.896240625180289;9.628524252492122;975.1149925155983;8.390779266560578;0.03263622125297896;0.8253454670833372;[AKT1]
GO:0050921;positive regulation of chemotaxis;6.0;0.6417349323569144;0.6439877787686017;8.362857879160845;97.3409382187974;4.886724499458715;0.003257913601026301;0.5730276307483924;[TGFB1]
GO:0033280;response to vitamin D;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;74.55580141320215;6.375876246018314;0.002495315577434836;0.6769819729871445;[TGFB1]
GO:0044255;cellular lipid metabolic process;4.0;0.38473765050673603;0.442368825253368;5.890854634208753;38.01953789122573;2.890541985149959;0.0012724797178566725;0.3978224515445179;[, NR1H2, FGF5, DGKZ, PPP2R1A, POR, TECR, PNPLA6]
GO:0001570;vasculogenesis;4.0;0.8933024483968273;0.6966512241984136;9.292052015870908;21.066225782797595;5.6339389012889365;7.050676185779127E-4;0.5381198974168686;[TGFB1]
GO:0060744;mammary gland branching involved in thelarche;8.0;1.0;0.875;9.628524252492122;74.22212479985593;8.16763571524637;0.002484147721475594;0.7926932703116032;[TGFB1]
GO:0000122;negative regulation of transcription by RNA polymerase II;11.0;0.6073376606709605;0.7360977826651425;8.793202583151634;1836.9481969605868;3.0544438328250214;0.0614810030062249;0.5886333519864981;[EHMT2, EZH2, AES, MMP12, NR1H2, TLE4, RFC1, E2F7, XPO1, TGFB1, CBX4, MEIS2]
GO:0045591;positive regulation of regulatory T cell differentiation;10.0;0.8933024483968273;0.861892236059334;9.60254876608886;997.8066164740876;7.292166977892469;0.03339568948573388;0.7881627702307852;[TGFB1]
GO:0070306;lens fiber cell differentiation;5.0;1.0;0.7902410118609202;9.628524252492122;24.20171999872632;7.212124270218933;8.100097882234571E-4;0.659069382437994;[TGFB1]
GO:0072718;response to cisplatin;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;29.728769549130092;7.697632086000634;9.949951626538169E-4;0.6838982747154925;[NUCB1]
GO:0045599;negative regulation of fat cell differentiation;6.0;0.9326813400603323;0.7894609826203107;9.541512875502493;114.62387697121986;5.948432231191374;0.0038363580074348307;0.6273234135236593;[TGFB1]
GO:0046326;positive regulation of glucose import;8.0;0.9326813400603323;0.8413406700301662;9.548481544818586;84.68372616907679;5.970411137910149;0.0028342881044734467;0.6803271032452366;[AKT1]
GO:0045116;protein neddylation;9.0;1.0;0.896240625180289;9.628524252492122;153.79381005389072;7.212124270218933;0.005147340417060716;0.7650689957573628;[UBE2M]
GO:0046329;negative regulation of JNK cascade;12.0;0.9326813400603323;0.9144609826203107;9.607904965289386;1764.4523437695266;6.280566066213989;0.05905463204195212;0.7693087532925187;[AKT1]
GO:1903911;positive regulation of receptor clustering;8.0;0.8933024483968273;0.8216512241984136;9.474373572664863;110.66472907477197;8.16763571524637;0.0037038488903424972;0.7926932703116032;[TGFB1]
GO:0048873;homeostasis of number of cells within a tissue;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;26.75021374699733;6.444869117505266;8.953055804826206E-4;0.6527112189764278;[CORO1A]
GO:0043066;negative regulation of apoptotic process;7.0;0.5640623033008358;0.6329505169076184;7.792313020693233;81.07407142393629;2.9735683700721314;0.0027134762086319553;0.5029877899877601;[AKT1, CLDN7, SFN, UNG, FLNA, CORO1A, ADAMTS20, POR, GNAI2, CBX4, NUP62]
GO:0043065;positive regulation of apoptotic process;7.0;0.5587538620495764;0.6302962962819887;7.806911820114386;80.91235068524658;3.3969510907807043;0.0027080635610472266;0.5246396020141064;[AKT1, SFN, AES, BIK, MELK, PPP2R1A, PPP1CA, TGFB1, UBE2M, DNM2]
GO:0046210;nitric oxide catabolic process;6.0;1.0;0.8231203125901445;9.628524252492122;265.80669839012444;9.777073627680469;0.008896310984619774;0.8231203125901445;[POR]
GO:0006909;phagocytosis;6.0;0.9326813400603323;0.7894609826203107;9.4949928598676;28.437470009997963;5.618190544320798;9.517765291732001E-4;0.610434838299289;[DNM2, CORO1A]
